Skip to main content
Premium Trial:

Request an Annual Quote

Caprion Licenses Antibody Technologies, Therapeutic Antibodies from Sunol Molecular

NEW YORK, June 7 (GenomeWeb News) - Caprion Pharmaceuticals has acquired humanized monoclonal antibody technologies as well as therapeutic antibodies from Miramar, Fla.-based Sunol Molecular, the company said today.

 

Caprion, based in Montreal, plans to apply the antibody technologies to develop therapeutics against tumor antigens it discovered using its proteomic profiling technology. Initially, the company will focus on solid tumors.

 

The therapeutic antibodies, which are currently in phase I clinical trials, are being developed to treat Hemolytic Uremic Syndrome resulting from E. coli infection.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.